Can a simple clinic visit predict cancer risk? new study aims to find out.
NCT ID NCT06926816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether offering genetic testing for cancer-related genes during regular gynecology visits is practical and acceptable for women aged 25 to 39. Researchers will track how many participants choose to get tested and how many have genetic changes that increase cancer risk. The goal is to make genetic testing more accessible without needing a specialist referral.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 39 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female patients between ages of 25-39 years at the time of visit 2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol. Exclusion Criteria: 1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers 2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable) 3. History of bilateral salpingo-oophorectomy 4. Visit related to pregnancy or immediately postpartum (within 2 weeks)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Genetic testing are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phone call could unlock early cancer detection for High-Risk groups
- Emotional support may ease distress during cancer genetic testing
- Can a digital guide boost genetic testing in prostate cancer survivors?
- New genetic counseling method may help breast cancer patients decide on surgery
- Could a simple blood test predict lung danger in heart defect patients?
- Phone cards boost screening confidence for pregnant patients